| 引用本文: | 龚小红,敖慧,张世洋,王晶,李芸霞,彭成.疾病以及配伍对人参皂苷在大鼠体内的药动学影响[J].中国现代应用药学,2019,36(20):2508-2512. |
| GONG Xiaohong,AO Hui,ZHANG Shiyang,WANG Jing,LI Yunxia,PENG Cheng.Study on the Pharmacokinetic Effects of Disease and Compatibility on Ginsenosides in Rats[J].Chin J Mod Appl Pharm(中国现代应用药学),2019,36(20):2508-2512. |
|
| 摘要: |
| 目的 建立SD大鼠血浆中人参皂苷Rb1、Rb2和Rg1的HPLC分析方法，对比分析配伍白术挥发油前后，人参皂苷在慢性萎缩性胃炎模型大鼠体内药动学特征。方法 SD大鼠分为4组，其中单用正常组和单用模型组均给药人参总皂苷292 mg·kg-1，配伍正常组和配伍模型组均给药人参总皂苷292 mg·kg-1和白术挥发油0.1 mL·kg-1。于给药前和给药后不同时间点进行眼眶取血，采用HPLC测定各成分的血药浓度，并采用Winnolin 6.3软件计算其药动学参数。结果 与单用正常大鼠比较，单用模型组大鼠体内人参皂苷Rb1的Cmax和AUC值降低，Tmax、T1/2以及MRT增加，人参皂苷Rb2和Rg1则呈现出AUC增加的变化；而配伍正常组大鼠体内人参皂苷Rb1、Rb2和Rg1的Cmax和AUC值均增加，Tmax、T1/2以及MRT值均缩短。与单用模型组大鼠比较，配伍模型组大鼠体内人参皂苷Rb1和Rg1的Cmax和AUC值均增加，Tmax、T1/2以及MRT值均降低。结论 在相同给药剂量下，疾病状态机体对人参皂苷的吸收和代谢呈现缓慢趋势，而配伍后能促进皂苷成分在体内的吸收，同时加快代谢消除，为人参的临床用药提供参考依据。 |
| 关键词: 人参皂苷 慢性萎缩性胃炎 配伍 药动学 |
| DOI：10.13748/j.cnki.issn1007-7693.2019.20.003 |
| 分类号:R969.1 |
| 基金项目:国家自然科学基金青年基金资助项目（81503272）；四川省科技厅面上项目（2017JY0187） |
|
| Study on the Pharmacokinetic Effects of Disease and Compatibility on Ginsenosides in Rats |
|
GONG Xiaohong, AO Hui, ZHANG Shiyang, WANG Jing, LI Yunxia, PENG Cheng
|
|
State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resources Co-founded by Sichuan Province and MOST/The Ministry of Education Key Laboratory of Standardization of Chinese Herbal, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
|
| Abstract: |
| OBJECTIVE To establish a specific HPLC method for the determination of ginsenoside Rb1, Rb2 and Rg1 in rat plamsa, and study the pharmacokinetic characteristics of ginsenoside in chronic atrophic gastritis rats before and after compatibility with atractylodes volatile oil. METHODS SD rats were randomly divided into 4 groups:the ginseng single-use normal group and the ginseng single-use model group(ginsenoside 292 mg·kg-1), the ginseng compatibility normal group and the ginseng compatibility model group(ginsenosides 292 mg·kg-1, atractylodes volatile oil 0.1 mL·kg-1). Plasma samples were collected from the orbital veins of rats at different time points after drug administration. The blood concentration of each component was determined by HPLC and its pharmacokinetic parameters were calculated by using Winnolin 6.3 software. RESULTS Compared with the single-use normal rats group, the Cmax and AUC values of ginsenoside Rb1 in single-use model group rats were decreased, Tmax, T1/2 and MRT were prolonged, the AUC values of ginsenoside Rb2 and Rg1 were increased; Cmax and AUC values of ginsenosides Rb1, Rb2 and Rg1 were increased in compatibility normal group rats, whereas Tmax, T1/2 and MRT were shortened. Compared with the single-use model group rats, Cmax and AUC values of ginsenosides Rb1 and Rg1 in compatibility model group rats were increased, Tmax, T1/2 and MRT were decreased. CONCLUSION At the same dose, the body's absorption and metabolism of ginsenosides showed a slow trend under the disease state, and the compatibility could accelerate the absorption of saponins in the body and accelerate the elimination of metabolism. It provides a reference for the clinical use of ginseng. |
| Key words: ginsenoside chronic atrophic gastritis compatibility pharmacokinetics |
